Abstract 2009
Background
The aim of our study was to determine the effect of homologous recombination gene deficiency (HRD) on the effectiveness of platinum chemotherapy and prognosis in patients with pancreatic cancer (PC).
Methods
PubMed and EMBASE database were processed. The search criteria included articles and abstracts till 16.01.2019. Primary outcome was hazard ratio (HR) for overall survival (OS) and 95% confidence interval (CI). Meta-analysis was conducted by «Review Manager» (RevMan) Ver. 5.3.
Results
The request identified 7038 records. A total of 4 studies were included in the meta-analysis and 16 in the systematic review. By the meta-analysis data HRD genotype didn’t affect the prognosis in resectable PC (HR = 1.03, 95% CI 0.46-2.33). By the systemic review average weighted median (AWM) OS for patients with HRD (n = 183) was 34.6 versus 27 months in patients without HRD (n = 1079). For patients who received platinum-based chemotherapy AWM OS was 46.1 months in group with HRD (n = 74) and 36.3 without the HRD (n = 227). For platinum-naive subgroup AWM OS was 24.2 months in HRD (n = 44) and 42.9 in non HRD patients (n = 134). The administration of platinum was associated with more favorable prognosis in HRD patients with resectable PC, but the differences weren`t statistically significant (HR = 0.60, 95% CI 0.36-1.33). For patients with advanced PC AWM OS was 19.8 months in group with HRD (n = 312) versus 15.6 months without HRD (n = 977). In subgroup with platinum, AWM OS was 23.8 and 17.1 months favoring HRD genotype. In subgroup without platinum, AWM OS was 8.3 months vs 12.0 months favoring HRD genotype.
Conclusions
HRD genotype is associated with poor prognosis. But administration of platinum-based chemotherapy can significantly improve the outcome in such a population of pts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
This research is conducted under the auspices of the experimental governmental assignment of the Ministry of Health of the Russian Federation and coordinated by the FSBI “Centre for Strategic Planning and Management of Biomedical Health Risks” of the Ministry of Health of the Russian Federation.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4317 - Prognostic factors analysis of 343 patients with adenocarcinoma of esophagogastric junction
Presenter: Yixun Lu
Session: Poster Display session 2
Resources:
Abstract
4099 - Effects of preoperative preparation time on efficacy of neoadjuvant chemotherapy (SOX) in patients with advanced gastric cancer
Presenter: Xinxin Wang
Session: Poster Display session 2
Resources:
Abstract
3769 - The prognostic value of higher absolute lymphocyte counts for patients with surgically resected non-advanced gastric cancer
Presenter: Se Jun Park
Session: Poster Display session 2
Resources:
Abstract
1718 - Trastuzumab and pertuzumab added to neoadjuvant chemoradiotherapy in resectable HER2+ esophageal adenocarcinoma patients: an update on survival and predictive biomarkers in the TRAP study
Presenter: Charlotte Stroes
Session: Poster Display session 2
Resources:
Abstract
5403 - Interim analysis of a phase II trial of perioperative chemotherapy plus avelumab in esophagogastric and gastric adenocarcinoma
Presenter: Thierry Alcindor
Session: Poster Display session 2
Resources:
Abstract
591 - Evaluation of the introduction of primary G-CSF prophylaxis to the FLOT chemotherapy regimen.
Presenter: Kelly-Marie Crampton
Session: Poster Display session 2
Resources:
Abstract
1402 - Subgroup analyses of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with 2 and 4 courses of cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) as neoadjuvant chemotherapy for locally advanced gastric cancer
Presenter: Tsutomu Hayashi
Session: Poster Display session 2
Resources:
Abstract
3743 - HER2 Copy Number as Predictor of Disease-Free Survival in HER2-Positive Resectable Gastric Cancer
Presenter: Zimin Liu
Session: Poster Display session 2
Resources:
Abstract
2032 - Effect of neoadjuvant chemotherapy on the Programmed Death-1 pathway in esophageal and gastric cancer
Presenter: Maria Svensson
Session: Poster Display session 2
Resources:
Abstract
4304 - A user-friendly nomogram to predict relapse-free survival (RFS) in western patients with resected gastric cancer (GC)
Presenter: Massimiliano Salati
Session: Poster Display session 2
Resources:
Abstract